Possibia

1286038

Last Update Posted: 2022-11-07

Recruiting has ended

All Genders

accepted

18 Years +

37 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

The purpose of this study is to evaluate the safety and efficacy of eltrombopag in people who have myelodysplastic syndrome (MDS) with thrombocytopenia who have progressed or are resistant to decitabine or azacitidine. (These are the only 2 drugs approved by the U.S. Food and Drug Administration [FDA] which can improve platelet counts). The investigators (the study doctor, study staff, and sponsor) want to find out what effects, good or bad, eltrombopag (study drug) may have on people with low platelet counts due to MDS. The investigators will also be testing how well eltrombopag may work at different doses in these diseases.

Study was originally designed as a Phase I/II but was terminated during the Phase I portion due to lack of efficacy

Eligibility

Relevant conditions:

Myelodysplastic Syndrome (MDS)

Thrombocytopenia

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov